Abstract 231P
Background
Our research is focused on vitamin D3 active form calcitriol and its analog tacalcitol, and their interactions on the immune system, including Th17 lymphocytes, which plays a significant role in the development and progression of breast cancer. The aim was to analyze the direct effect of vitamin D compounds on its nuclear receptors in Th17 cells and changes in IL-17 production. The interaction with osteopontin (OPN) was examined as the example of indirect influence on Th17 cells population in breast cancer. Taking into account the hormonal status during disease development and stimulation of the immune system, we used mice: 6-8 weeks old as a premenopausal and 35-40 weeks old, ovariectomized, as a postmenopausal model. Our research was mainly focused on CD4+ lymphocytes isolated from spleens, looking forward to Th17 helper lymphocytes differentiation after treatment.
Methods
Animals bearing EMT6 or E0771 murine mammary gland cancer tumours were administered with calcitriol or tacalcitol from day 7 after inoculation, every three days, in the dose of 0.5 μg/kg or 1 μg/kg body weight/day, respectively. Local Ethics Committee permission No 50/2020. CD4+ cells (splenocytes) were isolated, cultured and examined for subpopulation phenotype, differentiation into Th17, gene expression profile, OPN impact on Th17 differentiation, expression of OPN receptors.
Results
Both compounds inhibited E0771 tumor growth, but tacalcitol increased metastasis in aged mice. The growth of EMT-6 tumors was stimulated in young and inhibited in aged mice after tacalcitol treatment. Metastasis was inhibited independently of the age by tacalcitol. In the E0771 premenopausal and EMT6 postmenopausal groups, tacalcitol increased the number of gene transcripts for IL17. The same tendency was observed in the E0771 postmenopausal group for the Il17 and Rorc genes. Blocking of selected CD4+ surface receptors (CD44, CD51), related to OPN functions, resulted in an increase of iTh17 cells after tacalcitol treatment. Tacalcitol in iTh17 cells induced the mRNA level for VDR, OPN, IL-21 and IL17R coding genes.
Conclusions
The Th17 induction via the OPN plays an important role, especially after tacalcitol treatment. Both compounds affect Th17 lymphocytes depending on the tumor type and age of mice.
Legal entity responsible for the study
The authors.
Funding
The National Science Center, OPUS 18 grant No. 2019/35/B/NZ5/01250.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
109P - Efficacy of first-line immune-based combined systemic therapy and brain radiotherapy in patients with brain metastases (BM) from driver gene-negative NSCLC
Presenter: Mengxing You
Session: Poster Display session
110P - Safety and effectiveness of adebrelimab as first-line treatment in extensive-stage small-cell lung cancer: A prospective, real-world study
Presenter: Junxu Wen
Session: Poster Display session
111P - Real-world treatment patterns and clinical outcomes in Chinese stage III non-small cell lung cancer (NSCLC) patients: Results of MOOREA study
Presenter: Ligang Xing
Session: Poster Display session
112P - Serplulimab combined with chemotherapy and anlotinib for extensive-stage small-cell lung cancer: A multicenter real-world experience
Presenter: Jun Wang
Session: Poster Display session
113P - Clinical outcomes of avelumab and pembrolizumab in advanced urothelial cancer: An observational multicenter retro-prospective study on patients undergoing treatment in clinical practice (AVePEm study)
Presenter: Irene Torresan
Session: Poster Display session
115P - Immune-related adverse events in cancer patients treated with immune checkpoint inhibitors in Germany: A population-based study
Presenter: Lucie Heinzerling
Session: Poster Display session
116TiP - An umbrella trial (RECHALLENGE) to evaluate the safety and preliminary efficacy of combination or sequential immunotherapy in advanced solid tumor patients after disease progression in clinical trials
Presenter: Huilei Miao
Session: Poster Display session
122P - Intracellular adenosine drives profound lymphocyte suppression and can be reversed with EOS-984: A potent ENT1 antagonist
Presenter: Erica Houthuys
Session: Poster Display session
123P - Combination potential of EO-3021, a CLDN18.2 vc-MMAE ADC, with VEGFR2 or PD1 inhibition in preclinical models of CLDN18.2-expressing cancers
Presenter: Thomas O'Hare
Session: Poster Display session